<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>1822</id>
    <completedYear>2023</completedYear>
    <publishedYear/>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber/>
    <edition/>
    <issue>11</issue>
    <volume>15</volume>
    <type>article</type>
    <publisherName>MDPI</publisherName>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Comparison of Sonodynamic Treatment Set-Ups for Cancer Cells with Organic Sonosensitizers and Nanosonosensitizers</title>
    <abstract language="eng">Cancer sonodynamic therapy (SDT) is the therapeutic strategy of a high-frequency ultrasound (US) combined with a special sonosensitizer that becomes cytotoxic upon US exposure. The growing number of newly discovered sonosensitizers and custom US in vitro treatment solutions push the SDT field into a need for systemic studies and reproducible in vitro experimental set-ups. In the current research, we aimed to compare two of the most used and suitable SDT in vitro set-ups—“sealed well” and “transducer in well”—in one systematic study. We assessed US pressure, intensity, and temperature distribution in wells under US irradiation. Treatment efficacy was evaluated for both set-ups towards cancer cell lines of different origins, treated with two promising sonosensitizer candidates—carbon nanoparticle C60 fullerene (C60) and herbal alkaloid berberine. C60 was found to exhibit higher sonotoxicity toward cancer cells than berberine. The higher efficacy of sonodynamic treatment with a “transducer in well” set-up than a “sealed well” set-up underlined its promising application for SDT in vitro studies. The “transducer in well” set-up is recommended for in vitro US treatment investigations based on its US-field homogeneity and pronounced cellular effects. Moreover, SDT with C60 and berberine could be exploited as a promising combinative approach for cancer treatment.</abstract>
    <parentTitle language="eng">Pharmaceutics</parentTitle>
    <identifier type="issn">1999-4923</identifier>
    <identifier type="urn">urn:nbn:de:kobv:526-opus4-18223</identifier>
    <enrichment key="opus.import.date">2023-11-13T08:02:06+00:00</enrichment>
    <enrichment key="opus.source">sword</enrichment>
    <enrichment key="opus.import.user">sword</enrichment>
    <enrichment key="DOI_VoR">https://doi.org/10.3390/pharmaceutics15112616</enrichment>
    <enrichment key="SourceTitle">Radivoievych, A.; Prylutska, S.; Zolk, O.; Ritter, U.; Frohme, M.; Grebinyk, A. Comparison of Sonodynamic Treatment Set-Ups for Cancer Cells with Organic Sonosensitizers and Nanosonosensitizers. Pharmaceutics 2023, 15, 2616. https://doi.org/10.3390/pharmaceutics15112616</enrichment>
    <licence>Creative Commons - CC BY - Namensnennung 4.0 International</licence>
    <author>Aleksandar Radivoievych</author>
    <author>Svitlana Prylutska</author>
    <author>Oliver Zolk</author>
    <author>Uwe Ritter</author>
    <author>Marcus Frohme</author>
    <author>Anna Grebinyk</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>ultrasound</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>C60 fullerene</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>berberine</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>sonodynamic therapy</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>apoptosis</value>
    </subject>
    <collection role="ddc" number="570">Biowissenschaften; Biologie</collection>
    <collection role="institutes" number="">Fachbereich Ingenieur- und Naturwissenschaften</collection>
    <collection role="open_access" number="">open_access</collection>
    <collection role="Import" number="import">Import</collection>
    <collection role="Funding" number="">Publikationsfonds der TH Wildau</collection>
    <collection role="green_open_access" number="1">Gold Open Access</collection>
    <thesisPublisher>Technische Hochschule Wildau</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-th-wildau/files/1822/pharmaceutics-15-02616.pdf</file>
  </doc>
  <doc>
    <id>1943</id>
    <completedYear>2024</completedYear>
    <publishedYear/>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber/>
    <edition/>
    <issue>18</issue>
    <volume>16</volume>
    <type>article</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">From 2D to 3D In Vitro World: Sonodynamically-Induced Prooxidant Proapoptotic Effects of C60-Berberine Nanocomplex on Cancer Cells</title>
    <abstract language="eng">Recently, sonodynamic therapy (SDT) has emerged as a promising non-invasive approach for treating cancer by activating sensitizers with ultrasound (US). In this context, we investigated C60 fullerene (C60) as a nanocarrier for the promising drug Berberine (Ber)—both potential aromatic sonosensitizers. The preferential mitochondrial accumulation of C60 and the proapoptotic effects of Ber also make the C60-Berberine nanocomplex (C60-Ber) a good candidate for direct induction of the intrinsic apoptotic cell death under US action. The in vitro research on C60-Ber can provide insights into novel, non-invasive cancer treatments. These findings lead to the development of targeted therapies with reduced side effects, inspire interdisciplinary collaboration, and open new avenues for drug delivery and cancer therapy research.</abstract>
    <parentTitle language="eng">Cancers</parentTitle>
    <identifier type="urn">urn:nbn:de:kobv:526-opus4-19438</identifier>
    <enrichment key="opus.import.data">@articleRadivoievych2024, address = "Basel", publisher = "MDPI", eissn = "2072-6694", abstract = "Recently, sonodynamic therapy (SDT) has emerged as a promising non-invasive approach for treating cancer by activating sensitizers with ultrasound (US). In this context, we investigated C60 fullerene (C60) as a nanocarrier for the promising drug Berberine (Ber)—both potential aromatic sonosensitizers. The preferential mitochondrial accumulation of C60 and the proapoptotic effects of Ber also make the C60-Berberine nanocomplex (C60-Ber) a good candidate for direct induction of the intrinsic apoptotic cell death under US action. The in vitro research on C60-Ber can provide insights into novel, non-invasive cancer treatments. These findings lead to the development of targeted therapies with reduced side effects, inspire interdisciplinary collaboration, and open new avenues for drug delivery and cancer therapy research.", author = "Radivoievych, Aleksandar and Schnepel, Sophia and Prylutska, Svitlana and Ritter, Uwe and Zolk, Oliver and Frohme, Marcus and Grebinyk, Anna", doi = "10.3390/cancers16183184", journal = "Cancers", keywords = "Berberine, C60 fullerene, apoptosis, sonodynamic therapy, ultrasound", language = "eng", number = "18", pages = "3184", title = "From 2D to 3D In Vitro World: Sonodynamically-Induced Prooxidant Proapoptotic Effects of C60-Berberine Nanocomplex on Cancer Cells", volume = "16", year = "2024"</enrichment>
    <enrichment key="opus.import.dataHash">md5:a491ec6f9f210e1d83992a175d69f13e</enrichment>
    <enrichment key="opus.import.date">2024-09-18T10:16:38+00:00</enrichment>
    <enrichment key="opus.import.file">/tmp/phpx6oFfi</enrichment>
    <enrichment key="opus.import.format">bibtex</enrichment>
    <enrichment key="opus.import.id">66eaa886a41249.89077495</enrichment>
    <enrichment key="DOI_VoR">https://doi.org/10.3390/cancers16183184</enrichment>
    <enrichment key="SourceTitle">Radivoievych, A.; Schnepel, S.; Prylutska, S.; Ritter, U.; Zolk, O.; Frohme, M.; Grebinyk, A. From 2D to 3D In Vitro World: Sonodynamically-Induced Prooxidant Proapoptotic Effects of C60-Berberine Nanocomplex on Cancer Cells. Cancers 2024, 16, 3184. https://doi.org/10.3390/cancers16183184</enrichment>
    <licence>Creative Commons - CC BY - Namensnennung 4.0 International</licence>
    <author>Aleksandar Radivoievych</author>
    <author>Sophia Schnepel</author>
    <author>Svitlana Prylutska</author>
    <author>Uwe Ritter</author>
    <author>Oliver Zolk</author>
    <author>Marcus Frohme</author>
    <author>Anna Grebinyk</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>berberine</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>C60 fullerene</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>apoptosis</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>sonodynamic therapy</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>ultrasound</value>
    </subject>
    <collection role="ddc" number="571">Physiologie und verwandte Themen</collection>
    <collection role="ddc" number="616">Krankheiten</collection>
    <collection role="institutes" number="">Fachbereich Ingenieur- und Naturwissenschaften</collection>
    <collection role="open_access" number="">open_access</collection>
    <collection role="Funding" number="">Publikationsfonds der TH Wildau</collection>
    <collection role="green_open_access" number="1">Gold Open Access</collection>
    <thesisPublisher>Technische Hochschule Wildau</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-th-wildau/files/1943/cancers-16-03184-v2.pdf</file>
  </doc>
  <doc>
    <id>1062</id>
    <completedYear>2019</completedYear>
    <publishedYear>2019</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber/>
    <edition/>
    <issue/>
    <volume/>
    <type>article</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">A New Triple System DNA-Nanosilver-Berberine for Cancer Therapy</title>
    <abstract language="eng">The isoquinoline quaternary alkaloid Berberine possesses a variety of pharmacological properties that suggests its promising application for an anticancer delivery system design utilizing its ability to intercalate DNA.In the current work we have investigated the effects of Berberine on the human T-cell leukemia cell line in vitro.Fluorescent microscopy of leukemic cells revealed Berberine nuclear localization. The results showed that Berberine inhibited leukemic cell growth in a time-and dose-dependent manner, that was associated with reactive oxygen species production intensification and caspase 3/7 activity increase with followed apoptosis induction.Berberine was used as a toxic and phototoxic agent for triple system synthesis along with DNA as a carrier and nanosilver as a plasmonic accelerator of Berberine electronic transitions and high energy emission absorbent centers.The proposed method allows to obtain the complex of DNA with Berberine molecules and silver nanopoarticles. The optical properties of free components as well as their various combinations, including the final triple system DNA-Nanosilver-Berberine, were investigated. Obtained results support the possibility to use the triple system DNA-Nanosilver-Berberine as an alternative therapeutic agent for cancer treatment.</abstract>
    <parentTitle language="eng">Applied Nanoscience</parentTitle>
    <identifier type="issn">2190-5517</identifier>
    <identifier type="urn">urn:nbn:de:kobv:526-opus4-10628</identifier>
    <enrichment key="SourceTitle">Grebinyk, A., Yashchuk, V., Bashmakova, N., Gryn, D., Hagemann, T., Naumenko, A., et al. (2018). A new triple system DNA-Nanosilver-Berberine for cancer therapy. In Applied Nanoscience. http://dx.doi.org/10.1007/s13204-018-0688-x.</enrichment>
    <enrichment key="RelatedIdentifier">https://opus4.kobv.de/opus4-th-wildau/frontdoor/index/index/docId/1610</enrichment>
    <enrichment key="DOI_VoR">https://doi.org/10.1007/s13204-018-0688-x</enrichment>
    <licence>Das Dokument ist urheberrechtlich geschützt.</licence>
    <author>Anna Grebinyk</author>
    <author>Valeriy Yashchuk</author>
    <author>Nataliya Bashmakova</author>
    <author>Dmytro Gryn</author>
    <author>Tobias Hagemann</author>
    <author>Antonina Naumenko</author>
    <author>Nataliya Kutsevol</author>
    <author>Thomas Dandekar</author>
    <author>Marcus Frohme</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>berberine</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>apoptosis</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>nanosilver</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>DNA delivery system</value>
    </subject>
    <collection role="ddc" number="570">Biowissenschaften; Biologie</collection>
    <collection role="institutes" number="">Fachbereich Ingenieur- und Naturwissenschaften</collection>
    <collection role="open_access" number="">open_access</collection>
    <collection role="green_open_access" number="2">Green Open Access</collection>
    <thesisPublisher>Technische Hochschule Wildau</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-th-wildau/files/1062/Grebinyk_preprinted.pdf</file>
  </doc>
  <doc>
    <id>1293</id>
    <completedYear>2019</completedYear>
    <publishedYear/>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber/>
    <edition/>
    <issue>11</issue>
    <volume>11</volume>
    <type>article</type>
    <publisherName>MDPI</publisherName>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>2019-11-08</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">C60 Fullerene as an Effective Nanoplatform of Alkaloid Berberine Delivery into Leukemic Cells</title>
    <abstract language="eng">A herbal alkaloid Berberine (Ber), used for centuries in Ayurvedic, Chinese, Middle-Eastern, and native American folk medicines, is nowadays proved to function as a safe anticancer agent. Yet, its poor water solubility, stability, and bioavailability hinder clinical application. In this study, we have explored a nanosized carbon nanoparticle—C60 fullerene (C60)—for optimized Ber delivery into leukemic cells. Water dispersions of noncovalent C60-Ber nanocomplexes in the 1:2, 1:1, and 2:1 molar ratios were prepared. UV–Vis spectroscopy, dynamic light scattering (DLS), and atomic force microscopy (AFM) evidenced a complexation of the Ber cation with the negatively charged C60 molecule. The computer simulation showed that π-stacking dominates in Ber and C60 binding in an aqueous solution. Complexation with C60 was found to promote Ber intracellular uptake. By increasing C60 concentration, the C60-Ber nanocomplexes exhibited higher antiproliferative potential towards CCRF-CEM cells, in accordance with the following order: free Ber &lt; 1:2 &lt; 1:1 &lt; 2:1 (the most toxic). The activation of caspase 3/7 and accumulation in the sub-G1 phase of CCRF-CEM cells treated with C60-Ber nanocomplexes evidenced apoptosis induction. Thus, this study indicates that the fast and easy noncovalent complexation of alkaloid Ber with C60 improved its in vitro efficiency against cancer cells.</abstract>
    <parentTitle language="eng">Pharmaceutics</parentTitle>
    <identifier type="issn">1999-4923</identifier>
    <identifier type="urn">urn:nbn:de:kobv:526-opus4-12932</identifier>
    <enrichment key="opus.import.user">sword</enrichment>
    <enrichment key="opus.import.date">2019-12-12T23:05:01+00:00</enrichment>
    <enrichment key="opus.import.file">attachment; filename=deposit.zip</enrichment>
    <enrichment key="opus.import.checksum">d3b76ebd17631c1dd7d3f3f0bd6f6ea4</enrichment>
    <enrichment key="SourceTitle">Grebinyk, A., Prylutska, S., Buchelnikov, A., Tverdokhleb, N., Grebinyk, S., Evstigneev, M., et al. (2019). C60 Fullerene as an Effective Nanoplatform of Alkaloid Berberine Delivery into Leukemic Cells Pharmaceutics. 11 (11), 586.</enrichment>
    <enrichment key="DOI_VoR">https://doi.org/10.3390/pharmaceutics11110586</enrichment>
    <licence>Creative Commons - CC BY - Namensnennung 4.0 International</licence>
    <author>Anna Grebinyk</author>
    <author>Svitlana Prylutska</author>
    <author>Anatoliy Buchelnikov</author>
    <author>Nina Tverdokhleb</author>
    <author>Sergii Grebinyk</author>
    <author>Maxim Evstigneev</author>
    <author>Olga Matyshevska</author>
    <author>Vsevolod Cherepanov</author>
    <author>Yuriy Prylutskyy</author>
    <author>Valeriy Yashchuk</author>
    <author>Anton Naumovets</author>
    <author>Uwe Ritter</author>
    <author>Thomas Dandekar</author>
    <author>Marcus Frohme</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>C60 fullerene</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>berberine</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>noncovalent nanocomplex</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>UV–Vis</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>DLS and AFM measurements</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>drug release</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>leukemic cell</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>uptake</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>cytotoxicity</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>apoptosis</value>
    </subject>
    <collection role="ddc" number="570">Biowissenschaften; Biologie</collection>
    <collection role="institutes" number="">Fachbereich Ingenieur- und Naturwissenschaften</collection>
    <collection role="open_access" number="">open_access</collection>
    <collection role="Import" number="import">Import</collection>
    <collection role="Funding" number="">DFG-geförderter Publikationsfonds</collection>
    <collection role="green_open_access" number="1">Gold Open Access</collection>
    <thesisPublisher>Technische Hochschule Wildau</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-th-wildau/files/1293/pharmaceutics-11-00586-v2.pdf</file>
  </doc>
</export-example>
